Skip NavigationSkip to Content

HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses

  1. Author:
    Huang, J. H.
    Goedert, J. J.
    Sundberg, E. J.
    Cung, T. D. H.
    Burke, P. S.
    Martin, M. P.
    Preiss, L.
    Lifson, J.
    Lichterfeld, M.
    Carrington, M.
    Yu, X. G.
  2. Author Address

    [Huang, Jinghe; Cung, Thai Duong Hong; Burke, Patrick S.; Yu, Xu G.] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02129 USA. [Huang, Jinghe; Cung, Thai Duong Hong; Burke, Patrick S.; Yu, Xu G.] Harvard Univ, Boston, MA 02129 USA. [Goedert, James J.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA. [Sundberg, Eric J.] Boston Biomed Res Inst, Watertown, MA 02472 USA. [Martin, Maureen P.; Carrington, Mary] NCI, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA. [Lifson, Jeffrey] NCI, AIDS & Canc Virus Program, SAIC Frederick Inc, Frederick, MD 21702 USA. [Preiss, Liliana] Res Triangle Inst Int, Rockville, MD 20852 USA. [Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.;Yu, XG, Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02129 USA.;xyu@partners.org
    1. Year: 2009
    2. Date: Dec
  1. Journal: Journal of Experimental Medicine
    1. 206
    2. 13
    3. Pages: 2959-2966
  2. Type of Article: Article
  3. ISSN: 0022-1007
  1. Abstract:

    A subset of HLA-B*35 alleles, B*35-Px, are strongly associated with accelerated HIV-1 disease progression for reasons that are not understood. Interestingly, the alternative set of B*35 subtypes, B*35-PY, have no detectable impact on HIV-1 disease outcomes, even though they can present identical HIV-1 epitopes as B*35-Px molecules. Thus, the differential impact of these alleles on HIV-1 disease progression may be unrelated to interactions with HIV-1-specific CD8(+) T cells. Here, we show that the B*35-Px molecule B*3503 binds with greater affinity to immunoglobulin-like transcript 4 (ILT4), an inhibitory MHC class I receptor expressed on dendritic cells, than does the B*35-PY molecule B*3501, even though these two B*35 molecules differ by only one amino acid and present identical HIV-1 epitopes. The preferential recognition of B*3503 by ILT4 was associated with significantly stronger dendritic cell dysfunction in in vitro functional assays. Moreover, HIV-1-infected carriers of B*3503 had poor dendritic cell functional properties in ex vivo assessments when compared with carriers of the B*3501 allele. Differential interactions between HLA class I allele subtypes and immunoregulatory MHC class I receptors on dendritic cells thus provide a novel perspective for the understanding of MHC class I associations with HIV-1 disease progression and for the manipulation of host immunity against HIV-1.

    See More

External Sources

  1. DOI: 10.1084/jem.20091386
  2. WOS: 000272987500013

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel